Obalon Therapeutics
OverviewSuggest Edit
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
| Type | Public | |
| Founded | 2008 | |
| HQ | Carlsbad, US | Map |
| Website | obalon.com | |
| Employee Ratings | More |
Recent NewsAll News
- Obalon Therapeutics, Inc. Announces Two Agreements To Provide Up To $30 Million of Capital
- Global Intragastric Balloons Market 2018-2022 - Key Vendors are Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Lifesciences & Spatz FGIA
- Obalon Therapeutics to Raise $10 Million in Private Placement
- Obalon Therapeutics' (OBLN) CEO Andrew Rasdal on Q1 2018 Results - Earnings Call Transcript
Key People/Management at Obalon Therapeutics
Mark Brister
VP of R&D
Nooshin Hussainy
Financial Controller
Obalon Therapeutics Office Locations
Obalon Therapeutics has an office in Carlsbad
Carlsbad, US (HQ)
5421 Avenida Encinas f
Obalon Therapeutics Financials and Metrics
Obalon Therapeutics Revenue
Obalon Therapeutics's revenue was reported to be $9.10 m in FY, 2018
| USD | |
|---|---|
Revenue (Q2, 2019) | 386.0k |
Gross profit (Q2, 2019) | (293.0k) |
Gross profit margin (Q2, 2019), % | (75.9%) |
Net income (Q2, 2019) | (6.8m) |
EBIT (Q2, 2019) | (6.4m) |
Market capitalization (10-Jun-2019) | 29.6m |
Closing stock price (10-Jun-2019) | 1.0 |
Cash (30-Jun-2019) | 13.5m |
Obalon Therapeutics's current market capitalization is $29.6 m.
Annual
Quarterly
Annual
Annual
Quarterly
| USD | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (13.0m) | (7.7m) | (15.5m) | (24.6m) | (12.1m) | (21.9m) | (28.6m) | (8.3m) | (15.1m) |
Depreciation and Amortization | 142.0k | 66.0k | 136.0k | 221.0k | 129.0k | 276.0k | 428.0k | 150.0k | 256.0k |
Inventories | (75.0k) | (101.0k) | 80.0k | (84.0k) | (449.0k) | (424.0k) | (537.0k) | 102.0k | (157.0k) |
Accounts Payable | 519.0k | 217.0k | 58.0k | 534.0k | 1.1m | 275.0k | 135.0k | (137.0k) | (191.0k) |
| USD | Y, 2019 |
|---|---|
Revenue/Employee | 10.6k |
Financial Leverage | 2.3 x |
Obalon Therapeutics Online and Social Media Presence
Obalon Therapeutics's Trends
Obalon Therapeutics News and Updates
December 27, 2018
Obalon Therapeutics, Inc. Announces Two Agreements To Provide Up To $30 Million of Capital
SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into …
September 26, 2018
Global Intragastric Balloons Market 2018-2022 - Key Vendors are Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon Therapeutics, ReShape Lifesciences & Spatz FGIA
DUBLIN, Sept. 26, 2018 /PRNewswire/ -- The "Global Intragastric Balloons Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Intragastric Balloons Market to grow at a CAGR of 25.18% during the period 2018-2022. The report has been prepared based on an...
August 23, 2018
Obalon Therapeutics to Raise $10 Million in Private Placement
SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN) a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has entered into a…
Obalon Therapeutics Blogs
June 08, 2018
FDA Letter to Health Care Providers Related to Potential Risks, Including Death, with Liquid-Filled Intragastric Balloons for Weight Loss NOT Related to The Obalon Gas-Filled Balloon
No Reports of Deaths Related to Use of Obalon Six-Month Balloon System SAN DIEGO – […]
Obalon Therapeutics Frequently Asked Questions
When was Obalon Therapeutics founded?
Obalon Therapeutics was founded in 2008.
Who are Obalon Therapeutics key executives?
Obalon Therapeutics's key executives are Mark Brister and Nooshin Hussainy.
How many employees does Obalon Therapeutics have?
Obalon Therapeutics has 36 employees.
What is Obalon Therapeutics revenue?
Latest Obalon Therapeutics annual revenue is $9.1 m.
What is Obalon Therapeutics revenue per employee?
Latest Obalon Therapeutics revenue per employee is $252.8 k.
Who are Obalon Therapeutics competitors?
Competitors of Obalon Therapeutics include VisCardia, Tactile Medical and Respicardia.
Where is Obalon Therapeutics headquarters?
Obalon Therapeutics headquarters is located at 5421 Avenida Encinas f, Carlsbad.
Where are Obalon Therapeutics offices?
Obalon Therapeutics has an office in Carlsbad.
How many offices does Obalon Therapeutics have?
Obalon Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies